CO6531497A2 - Inhibidores cíclico péptido de la replicación del virus de la hepatitis c - Google Patents

Inhibidores cíclico péptido de la replicación del virus de la hepatitis c

Info

Publication number
CO6531497A2
CO6531497A2 CO12069712A CO12069712A CO6531497A2 CO 6531497 A2 CO6531497 A2 CO 6531497A2 CO 12069712 A CO12069712 A CO 12069712A CO 12069712 A CO12069712 A CO 12069712A CO 6531497 A2 CO6531497 A2 CO 6531497A2
Authority
CO
Colombia
Prior art keywords
heterocyclic compounds
methods
compounds containing
hepatitis
derivatives
Prior art date
Application number
CO12069712A
Other languages
English (en)
Spanish (es)
Inventor
Brad O Buckman
John B Nicholas
Leonid Beigelman
Vladimir Serebryany
Antitsa Stoycheva
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of CO6531497A2 publication Critical patent/CO6531497A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CO12069712A 2009-09-28 2012-04-27 Inhibidores cíclico péptido de la replicación del virus de la hepatitis c CO6531497A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24646509P 2009-09-28 2009-09-28
US32425110P 2010-04-14 2010-04-14
US34573710P 2010-05-18 2010-05-18
US34623810P 2010-05-19 2010-05-19

Publications (1)

Publication Number Publication Date
CO6531497A2 true CO6531497A2 (es) 2012-09-28

Family

ID=43796242

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12069712A CO6531497A2 (es) 2009-09-28 2012-04-27 Inhibidores cíclico péptido de la replicación del virus de la hepatitis c

Country Status (19)

Country Link
US (1) US20110081315A1 (enExample)
EP (1) EP2483290A4 (enExample)
JP (1) JP2013505952A (enExample)
KR (1) KR20130026410A (enExample)
CN (2) CN105001302A (enExample)
AR (1) AR078462A1 (enExample)
AU (1) AU2010298028A1 (enExample)
CA (1) CA2775697A1 (enExample)
CO (1) CO6531497A2 (enExample)
EA (1) EA201290128A1 (enExample)
EC (1) ECSP12011845A (enExample)
IL (1) IL218766A0 (enExample)
IN (1) IN2012DN02693A (enExample)
MA (1) MA33720B1 (enExample)
MX (1) MX2012003500A (enExample)
PH (1) PH12012500602A1 (enExample)
TN (1) TN2012000135A1 (enExample)
TW (1) TW201124137A (enExample)
WO (1) WO2011038293A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008001166A (es) * 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
US8119592B2 (en) * 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
BRPI0911260A2 (pt) * 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
WO2011107530A2 (en) * 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
MX2012014301A (es) 2010-06-07 2013-04-29 Enanta Pharm Inc Inhibidores macrociclicos de serina proteasa de hepatitis c.
CA2811025C (en) 2010-09-10 2018-07-17 Shionogi & Co., Ltd. Hetero ring-fused imidazole derivative having ampk activating effect
US20120101032A1 (en) * 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013041655A1 (en) * 2011-09-22 2013-03-28 Janssen Pharmaceuticals, Inc. Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
EP2863738A2 (en) 2012-06-14 2015-04-29 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
RU2015144103A (ru) 2013-03-15 2017-04-28 Зингента Партисипейшнс Аг Микробиоцидно-активные имидазопиридиновые производные
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
WO2016127859A1 (en) * 2015-02-13 2016-08-18 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c inhibitors and uses thereof in medicine
CN108314648A (zh) * 2018-04-12 2018-07-24 苏州康润医药有限公司 4-溴-7-氟异喹啉的合成方法
CN110305018B (zh) * 2019-06-06 2022-07-15 浙江普洛家园药业有限公司 一种3-溴-2-氟硝基苯的制备方法
CN112358447B (zh) * 2020-11-16 2022-04-12 苏州康润医药有限公司 7-氟异喹啉-1-羧酸的合成方法
CN114105800B (zh) * 2021-11-25 2023-09-01 杭州国瑞生物科技有限公司 一种2,3-二氨基苯甲酸甲酯的制备方法
WO2025257072A1 (en) * 2024-06-14 2025-12-18 Syngenta Crop Protection Ag Pesticidally active 2-oxobenzimidazole compounds
CN119143611A (zh) * 2024-11-15 2024-12-17 浙江大学衢州研究院 一种n-异丙基对氟苯胺的连续制备方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
US5552558A (en) 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
GB8918806D0 (en) * 1989-08-17 1989-09-27 Shell Int Research Chiral compounds,their preparation and use
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
KR100187990B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6693072B2 (en) * 1994-06-02 2004-02-17 Aventis Pharmaceuticals Inc. Elastase inhibitors
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6277830B1 (en) 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
DE60137207D1 (de) * 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
MXPA02010375A (es) * 2000-04-19 2003-04-25 Schering Corp Inhibidores macrociclicos de la ns3-serina proteasa del virus de la hepatitis c que comprenden porciones alquil y arilalanina p2.
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2002248147B2 (en) * 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
US6858600B2 (en) * 2001-05-08 2005-02-22 Yale University Proteomimetic compounds and methods
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
AU2003223602B8 (en) * 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003248535A1 (en) * 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
EP1505945B1 (en) * 2002-05-20 2008-11-05 Bristol-Myers Squibb Company Substituted cycloalkyl p1' hepatitis c virus inhibitors
JP4312718B2 (ja) * 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
PL199412B1 (pl) * 2002-10-15 2008-09-30 Boehringer Ingelheim Int Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania
CA2522205A1 (en) * 2003-04-10 2004-10-28 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
EP1613620A1 (en) * 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ES2320771T3 (es) * 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
PL1615613T3 (pl) * 2003-04-18 2010-04-30 Enanta Pharm Inc Chinoksalinylowe makrocykliczne inhibitory proteazy serynowej zapalenia wątroby typu C
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
CA2541634A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005037214A2 (en) * 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7939538B2 (en) * 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
CA2573346C (en) * 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7550559B2 (en) * 2004-08-27 2009-06-23 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
EP1794179A1 (en) * 2004-09-17 2007-06-13 Boehringer Ingelheim International Gmbh Ring-closing metathesis process in supercritical fluid
AU2006242475B2 (en) * 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI389908B (zh) * 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
US7470664B2 (en) * 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
MX2008001166A (es) * 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
JP5230417B2 (ja) * 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大員環インヒビター
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
MX2008001528A (es) * 2005-08-02 2008-04-04 Vertex Pharma Inhibidores de serina proteasas.
US8119592B2 (en) * 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0618610A2 (pt) * 2005-11-16 2011-09-06 Hoffmann La Roche derivados de pirrolidina como inibidores de fator xa de coagulação
US7728148B2 (en) * 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP2049474B1 (en) * 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MX2009000486A (es) * 2006-07-13 2009-01-27 Achillion Pharmaceuticals Inc Peptidos de 4-amino-4-oxobutanoilo como inhibidores de replicacion viral.
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
WO2008019289A2 (en) * 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US20090035267A1 (en) * 2007-07-31 2009-02-05 Moore Joel D Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
US7718612B2 (en) * 2007-08-02 2010-05-18 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US7662779B2 (en) * 2006-08-11 2010-02-16 Enanta Pharmaceuticals, Inc. Triazolyl macrocyclic hepatitis C serine protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7687459B2 (en) * 2006-08-11 2010-03-30 Enanta Pharmaceuticals, Inc. Arylalkoxyl hepatitis C virus protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20080038225A1 (en) * 2006-08-11 2008-02-14 Ying Sun Triazolyl acyclic hepatitis c serine protease inhibitors
US20090035268A1 (en) * 2007-08-01 2009-02-05 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
US8343477B2 (en) * 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US20080107625A1 (en) * 2006-11-01 2008-05-08 Bristol-Myers Squibb Company Inhibitors of Hepatitis C Virus
US7772180B2 (en) * 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2097402T3 (da) * 2006-11-17 2014-06-30 Janssen R & D Ireland Makrocykliske inhibitorer af hepatitis c-virus
CA2676297A1 (en) * 2007-02-16 2008-08-21 Boehringer Ingelheim International Gmbh Inhibitors of hepatitis c ns3 protease
US20100074867A1 (en) * 2007-03-23 2010-03-25 Schering Corporation Patent Department, K-6-1; 1990 P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
US20090123423A1 (en) * 2007-04-26 2009-05-14 Yonghua Gai Hydroxyamic analogs as hepatitis c virus serine protease inhibitor
AP2009005053A0 (en) 2007-05-03 2009-12-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
US8093257B2 (en) * 2007-05-04 2012-01-10 Bristol-Myers Squibb Company [6,5]-bicyclic GPR119 G protein-coupled receptor agonists
MX2009012093A (es) * 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
US20090005387A1 (en) * 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
AP2009005073A0 (en) * 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
WO2009014730A1 (en) * 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
US20090060874A1 (en) * 2007-09-05 2009-03-05 Yao-Ling Qiu Bicyclic pyrrolidine derivatives
WO2009042668A2 (en) * 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US20090082366A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched telaprevir
BRPI0817881A2 (pt) * 2007-10-10 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
US20090111757A1 (en) * 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8383583B2 (en) * 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
JP2011503231A (ja) * 2007-11-20 2011-01-27 コンサート ファーマシューティカルズ インコーポレイテッド Ｈｃｖ感染処置のためのペプチド
AU2008340430B2 (en) * 2007-12-21 2013-01-24 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
BRPI0911260A2 (pt) * 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
BRPI0913677A2 (pt) * 2008-07-02 2015-12-15 Idenix Pharmaceuticals Inc composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101647520B1 (ko) * 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MY152824A (en) * 2008-09-17 2014-11-28 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin.
US8603737B2 (en) * 2008-09-19 2013-12-10 Celgene Avilomics Research, Inc. Methods for identifying HCV protease inhibitors
US20100080770A1 (en) * 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8044087B2 (en) * 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
AU2009316472B2 (en) * 2008-11-20 2015-07-09 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus
US20110064694A1 (en) * 2009-09-09 2011-03-17 Yale University Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) * 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031904A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
AU2009352688B2 (en) * 2009-09-15 2014-04-17 Taigen Biotechnology Co., Ltd. HCV protease inhibitors
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides

Also Published As

Publication number Publication date
AR078462A1 (es) 2011-11-09
EP2483290A1 (en) 2012-08-08
AU2010298028A2 (en) 2012-10-04
WO2011038293A1 (en) 2011-03-31
IN2012DN02693A (enExample) 2015-09-04
EP2483290A4 (en) 2013-05-01
CN102741270A (zh) 2012-10-17
IL218766A0 (en) 2012-06-28
MA33720B1 (fr) 2012-11-01
CA2775697A1 (en) 2011-03-31
CN102741270B (zh) 2015-07-22
ECSP12011845A (es) 2012-06-29
MX2012003500A (es) 2012-08-01
CN105001302A (zh) 2015-10-28
TW201124137A (en) 2011-07-16
AU2010298028A1 (en) 2012-04-19
KR20130026410A (en) 2013-03-13
EA201290128A1 (ru) 2013-01-30
US20110081315A1 (en) 2011-04-07
JP2013505952A (ja) 2013-02-21
TN2012000135A1 (en) 2013-09-19
PH12012500602A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
CO6531497A2 (es) Inhibidores cíclico péptido de la replicación del virus de la hepatitis c
BR112013003101A2 (pt) inibidores do vírus da hepatite c
BR112013002729A2 (pt) inibidores de vírus de hepatite c
BR112012018529A2 (pt) inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna
BR112013028679A2 (pt) inibidores do vírus da hepatite c
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
BR112014033080A2 (pt) inibidores do vírus da hepatite c
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
MX375432B (es) Inhibidores de la replicacion de los virus de la gripe.
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
EA200900184A1 (ru) 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BR112013006693A2 (pt) inibidores da serino protease hcv derivada de prolina macrocílcica
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
EA201791776A1 (ru) Замещенные циклофаны для использования при лечении инфекции вгс
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
EA201001276A1 (ru) Ингибиторы вируса гепатита с
BR122012005261A8 (pt) Inibidores de protease de serina para hepatite c macrocíclica no tratamento de infecção por hcv
CL2012001960A1 (es) Compuestos derivados de ácido tiofeno-2-carboxílico; inhibidores de virus flaviviridae; composición farmacéutica que los comprende; utiles en el tratamiento de la hepatitis c. pct fase nacional
BR112013007696A2 (pt) composto, composição farmacêutica, usos do referido composto e da referida composição
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c
ECSP21067189A (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb
BR112013001132A2 (pt) processo para preparação de compostos antivirais
MX393113B (es) Derivados de pirrolopirimidina utiles como inhibidores de la replicacion de los virus de la gripe.

Legal Events

Date Code Title Description
FA Application withdrawn